ArticleAnnals of surgical oncology2026
Elevated Pre-Treatment Serum Interleukin-10 Levels Predict Poor Overall Survival in Esophageal Cancer.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveOur objective was to evaluate whether pre-treatment serum interleukin (IL)-10 concentrations predicted overall survival (OS) in patients with esophageal squamous cell carcinoma.
methodsThis single-center retrospective analysis included 112 patients with esophageal cancer who were treated with definitive concurrent chemoradiotherapy. Pre-treatment serum samples were collected, and IL-10 levels were measured. Patients were dichotomized into "low" and "high" IL-10 groups. Baseline characteristics (age, alcohol consumption, betel nut chewing, smoking, clinical T/N stage, Union for International Cancer Control [UICC] stage, tumor grade, primary location, and treatment) were compared using χ
resultsBaseline demographics and clinicopathological characteristics were comparable between the low- and high-IL-10 groups. The 1- and 3-year OS rates were 85% and 50% in the low-IL-10 group and 56% and 33% in the high-IL-10 group, respectively. Univariate analysis indicated that UICC stage and IL-10 level influenced prognosis. Advanced stage and high IL-10 expression were independent predictors of shorter OS and progression-free survival. Kaplan-Meier curves showed that survival diverged early between the IL-10 strata and remained separated over time.
conclusionsHigh pre-treatment serum IL-10 levels were associated with worse survival in patients with esophageal squamous cell carcinoma and constituted an independent prognostic factor after adjusting for clinical stage. As a minimally invasive biomarker, serum IL-10 can aid in risk stratification and may inform immunomodulatory treatment strategies.
Indexed as
Identifiers
42634054What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.